Sign in
Taking peopleNo phase

Calcitonin given early to affect nerve pain after spinal cord injury

Tests calcitonin against placebo for nerve pain in adults with spinal cord injury.

Key facts

Who runs it
Tanta University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury
Status
Recruiting
People taking part
126 people, planned
Started
1 May 2023
Expected to end
1 May 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Calcitonin
  • Placebo
Record updated
14 May 2026

Who can take part

The trial is looking for adults with a recent spinal cord injury. It tests whether early calcitonin lowers the chance or severity of nerve pain.

Age
18 years and older
Sex
All sexes
Disease stage
Spinal cord injury at any level and any degree of completeness, in the early stage after the injury.
Earlier treatment
People taking anticonvulsant (anti-seizure) medicines cannot join.
Main reasons for not taking part
  • Taking anticonvulsant medicines
  • Already having signs of nerve (neuropathic) pain
  • Past allergic reaction to calcitonin
  • Kidney, liver or heart problems, or neurological disorders
  • Brain damage or major injury to the arms, legs or belly
Show the full registry criteria (6)Hide the full registry criteria

Who can take part

  • Patients aged ≥18 years, with spinal cord injury at any level and any degree of completeness in the early stage of trauma

Who cannot take part

  • Intake of anticonvulsants medications
  • Evidence of previous allergic reaction to calcitonin
  • Patients with renal, hepatic and cardiac dysfunction or neurological disorders
  • Evidence of neuropathic pain
  • brain damage or major trauma to extremities or abdomen

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Calcitonin or neuropathic pain or spinal cord injury

This trial is currently available in Egypt.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective randomized double blinded study will be conducted to evaluate the effect of early pharmacologic intervention with calcitonin on the incidence or the severity of neuropathic pain after spinal cord injury

The 2 groups in the trial

  • Calcitonin groupTreatment being tested

    patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.

    Treatment: Calcitonin

  • Placebo groupPlacebo, for comparison

    patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.

    Treatment: Placebo

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Early Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury
Plain-language title
Calcitonin given early to affect nerve pain after spinal cord injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT05805683, who can take part
Record updated
14 May 2026